Fibrin-Targeting Immunotherapy for Neuroinflammatory & Neurodegenerative Diseases
- Vascular dysfunction leads to the toxic accumulation of fibrin deposits outside of blood vessels, sparking chronic innate immune cell activation; this emerging pathway represents a novel, highly specific target for neurodegenerative disease intervention
- Targeting this pathway with highly specific antibodies restores a beneficial microglial population and is protective in preclinical models of Alzheimer’s disease, multiple sclerosis, and retinal diseases
- THN391, a first-in-class high-affinity humanized monoclonal antibody targeting the fibrin inflammatory epitope, is in Phase 1b trials for early Alzheimer's disease and diabetic macular edema